Active Ingredient(s): Vestronidase alfa-vjbk
FDA Approved: * November 15, 2017
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Mepsevii Overview

Sly syndrome, also called mucopolysaccharidosis type VII (MPS-VII), is an autosomal recessive lysosomal storage disease caused by a deficiency of the enzyme β-glucuronidase. This enzyme is responsible for breaking down large sugar molecules called glycosaminoglycans (AKA GAGs, or mucopolysaccharides). The inability to break down GAGs leads to a buildup in many tissues and organs of the body. The severity of the disease can vary widely.[1] Contents 1 Signs and symptoms 2...

Read more Mepsevii Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Mepsevii Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Vestronidase alfa-vjbk
  • Injection: 10mg/5ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Mepsevii: (1 result)

Sorted by National Drug Code
  • 69794-001 Mepsevii 2 mg/ml Intravenous Injection by Ultragenyx Pharmaceutical Inc.

Other drugs which contain Vestronidase alfa-vjbk or a similar ingredient: (1 result)